Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations

ABSTRACT In human immunodeficiency virus type 1 (HIV-1) subtype B, CXCR4 coreceptor use ranges from ∼20% in early infection to ∼50% in advanced disease. Coreceptor use by non-subtype B HIV is less well characterized. We studied coreceptor tropism of subtype A and D HIV-1 collected from 68 pregnant, antiretroviral drug-naive Ugandan women (HIVNET 012 trial). None of 33 subtype A or 10 A/D-recombinant viruses used the CXCR4 coreceptor. In contrast, nine (36%) of 25 subtype D viruses used both CXCR4 and CCR5 coreceptors. Clonal analyses of the nine subtype D samples with dual or mixed tropism revealed heterogeneous viral populations comprised of X4-, R5-, and dual-tropic HIV-1 variants. In five of the six samples with dual-tropic strains, V3 loop sequences of dual-tropic clones were identical to those of cocirculating R5-tropic clones, indicating the presence of CXCR4 tropism determinants outside of the V3 loop. These dual-tropic variants with R5-tropic-like V3 loops, which we designated “dual-R,” use CCR5 much more efficiently than CXCR4, in contrast to dual-tropic clones with X4-tropic-like V3 loops (“dual-X”). These observations have implications for pathogenesis and treatment of subtype D-infected individuals, for the association between V3 sequence and coreceptor tropism phenotype, and for understanding potential mechanisms of evolution from exclusive CCR5 use to efficient CXCR4 use by subtype D HIV-1.

[1]  Rami Kantor,et al.  High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.

[2]  L. Ratner,et al.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants , 1996, Journal of virology.

[3]  D. Pieniążek,et al.  Predominance of HIV-1 subtype A and D infections in Uganda. , 2000, Emerging infectious diseases.

[4]  B. Moser Chemokines and HIV: a remarkable synergism. , 1997, Trends in microbiology.

[5]  C. Luo,et al.  A molecular epidemiologic survey of HIV in Uganda , 1998, AIDS.

[6]  M. Peeters,et al.  Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[7]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[8]  T. Leitner,et al.  CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. , 2006, The Journal of general virology.

[9]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[10]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[11]  J. Hoxie,et al.  Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent , 1997, Journal of virology.

[12]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[13]  Eoin Coakley,et al.  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Susan Zolla-Pazner,et al.  Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity. , 2003, AIDS research and human retroviruses.

[15]  D. Ho,et al.  HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. , 1997, AIDS research and human retroviruses.

[16]  T. F. Rinke de Wit,et al.  HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.

[17]  Jaap Goudsmit,et al.  N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.

[18]  S. Engelbrecht,et al.  Genotypic and phenotypic analysis of the env gene from South African HIV‐1 subtype B and C isolates , 2002, Journal of medical virology.

[19]  L. Morris,et al.  CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. , 2001, AIDS research and human retroviruses.

[20]  V. Robison,et al.  Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives. , 2002, AIDS research and human retroviruses.

[21]  Lynn Morris,et al.  A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences , 2006, Journal of Virology.

[22]  P. Harrigan,et al.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.

[23]  J. Albert,et al.  Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.

[24]  H. Schuitemaker,et al.  Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR , 1995, Journal of clinical microbiology.

[25]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[26]  J. Albert,et al.  REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.

[27]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[28]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[29]  D. Ho,et al.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry , 1997, Journal of virology.

[30]  D. Schols HIV co-receptor inhibitors as novel class of anti-HIV drugs. , 2006, Antiviral research.

[31]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[32]  Sudhir Kumar,et al.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment , 2004, Briefings Bioinform..

[33]  F. Barré-Sinoussi,et al.  Coreceptor Usage of HIV‐1 Isolates Representing Different Genetic Subtypes Obtained From Pregnant Cameroonian Women , 2000, Journal of acquired immune deficiency syndromes.

[34]  Bhavna Chohan,et al.  HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. , 2007, The Journal of infectious diseases.

[35]  Lynn Morris,et al.  The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.

[36]  N. Graham,et al.  HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.

[37]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[38]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial , 2003, The Lancet.

[39]  P. Illei,et al.  Definition of the range and distribution of human immunodeficiency virus macrophage tropism using PCR-based infectivity measurements. , 1994, The Journal of general virology.

[40]  A. Halpern,et al.  A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. , 1995, AIDS research and human retroviruses.

[41]  R. Shafer,et al.  Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D. , 2002, AIDS research and human retroviruses.

[42]  M. Salminen,et al.  Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. , 2002, AIDS research and human retroviruses.

[43]  D. Burke,et al.  Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. , 1995, AIDS research and human retroviruses.

[44]  W. Fawzi,et al.  Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Albert,et al.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates , 1988, Journal of virology.

[46]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[47]  L. Ratner,et al.  Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations , 2006, Journal of Virology.

[48]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[49]  L. Mofenson,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow up of the HIVNET 012 randomized trial , 2004 .

[50]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[51]  F. Barré-Sinoussi,et al.  Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European Network for In Utero Transmission of HIV-1. , 2000 .

[52]  M. Dittmar,et al.  The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. , 2002, Virology.

[53]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[54]  Noah G. Hoffman,et al.  Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.

[55]  Characterization,et al.  Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. , 1994, AIDS research and human retroviruses.